Citius Pharmaceuticals (CTXR) Common Equity (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Common Equity came in at $61.5 million in Q1 2026, down 3.2% YoY from $63.6 million in Q1 2025, and down 34.16% on a QoQ basis from $93.5 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Common Equity (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Common Equity data on file, last reported at $61.5 million in Q1 2026.
- Quarterly Common Equity fell 3.2% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 million (down 3.2% YoY) and the FY2025 annual result came in at $77.5 million, up 4.62% from the prior year.
- Common Equity eased to $61.5 million in Q1 2026, from $93.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $118.2 million in Q1 2022 to a low of $98300.2 in Q2 2023.
- A 5-year average of $80.7 million and a median of $85.3 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 99.91% — and 2024, when it surged 87676.33%.
- Tracing CTXR's Common Equity over 5 years: stood at $101.0 million in 2022, then declined by 15.54% to $85.3 million in 2023, then declined by 19.24% to $68.9 million in 2024, then jumped by 35.62% to $93.5 million in 2025, then sank by 34.16% to $61.5 million in 2026.
- The last three Common Equity figures came in at $61.5 million (Q1 2026), $93.5 million (Q4 2025), and $77.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.79 Bn |
| 10 | Citius Pharmaceuticals | 15.97 Mn | 15.97 Mn | 1.00 Mn | 75.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.54 Mn |
| Dec 31, 2025 | 93.47 Mn |
| Sep 30, 2025 | 77.53 Mn |
| Jun 30, 2025 | 65.06 Mn |
| Mar 31, 2025 | 63.58 Mn |
| Dec 31, 2024 | 68.92 Mn |
| Sep 30, 2024 | 74.10 Mn |
| Jun 30, 2024 | 86.28 Mn |
| Mar 31, 2024 | 79.97 Mn |
| Dec 31, 2023 | 85.33 Mn |
| Sep 30, 2023 | 91.43 Mn |
| Jun 30, 2023 | 98,300.17 |
| Mar 31, 2023 | 91.81 Mn |
| Dec 31, 2022 | 101.03 Mn |
| Sep 30, 2022 | 103.43 Mn |
| Jun 30, 2022 | 110.34 Mn |
| Mar 31, 2022 | 118.20 Mn |
| Dec 31, 2021 | 124.56 Mn |
| Sep 30, 2021 | 132.78 Mn |
| Jun 30, 2021 | 137.28 Mn |